BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 25318750)

  • 1. Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.
    Li F; Zheng C; Zhong Y; Zeng C; Xu F; Yin R; Jiang Q; Zhou M; Liu Z
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1903-11. PubMed ID: 25318750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis.
    Huang J; Liu G; Zhang YM; Cui Z; Wang F; Liu XJ; Chu R; Zhao MH
    BMC Med; 2014 May; 12():81. PubMed ID: 24884842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.
    Jin J; Li YW; He Q
    Transplant Proc; 2015; 47(6):1760-5. PubMed ID: 26293047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome].
    Segarra A; Jatem E; Quiles MT; Arbós MA; Ostos H; Valtierra N; Carnicer C; Agraz I; Salcedo MT
    Nefrologia; 2014; 34(1):46-52. PubMed ID: 24463862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum soluble urokinase type plasminogen activated receptor and focal segmental glomerulosclerosis: a systematic review and meta-analysis.
    Shuai T; Pei Jing Y; Huang Q; Xiong H; Liu J; Zhu L; Yang K; Jian L
    BMJ Open; 2019 Oct; 9(10):e031812. PubMed ID: 31594897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.
    Bock ME; Price HE; Gallon L; Langman CB
    Clin J Am Soc Nephrol; 2013 Aug; 8(8):1304-11. PubMed ID: 23620441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.
    Huang J; Liu G; Zhang YM; Cui Z; Wang F; Liu XJ; Chu R; Chen Y; Zhao MH
    Kidney Int; 2013 Aug; 84(2):366-72. PubMed ID: 23447064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
    Cara-Fuentes G; Wei C; Segarra A; Ishimoto T; Rivard C; Johnson RJ; Reiser J; Garin EH
    Pediatr Nephrol; 2014 Aug; 29(8):1363-71. PubMed ID: 24263531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.
    Sinha A; Bajpai J; Saini S; Bhatia D; Gupta A; Puraswani M; Dinda AK; Agarwal SK; Sopory S; Pandey RM; Hari P; Bagga A
    Kidney Int; 2014 Mar; 85(3):649-58. PubMed ID: 24429405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease.
    Spinale JM; Mariani LH; Kapoor S; Zhang J; Weyant R; Song PX; Wong HN; Troost JP; Gadegbeku CA; Gipson DS; Kretzler M; Nihalani D; Holzman LB;
    Kidney Int; 2015 Mar; 87(3):564-74. PubMed ID: 25354239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method.
    Winnicki W; Sunder-Plassmann G; Sengölge G; Handisurya A; Herkner H; Kornauth C; Bielesz B; Wagner L; Kikić Ž; Pajenda S; Reiter T; Schairer B; Schmidt A
    Sci Rep; 2019 Sep; 9(1):13783. PubMed ID: 31551522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].
    Segarra A; Jatem E; Quiles MT; Arbós MA; Ostos H; Valtierra N; Carnicer C; Salcedo MT
    Nefrologia; 2014; 34(1):53-61. PubMed ID: 24463863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating suPAR as a biomarker of disease severity in children with proteinuric glomerulonephritis.
    Sołtysiak J; Zachwieja J; Benedyk A; Lewandowska-Stachowiak M; Nowicki M; Ostalska-Nowicka D
    Minerva Pediatr; 2019 Feb; 71(1):4-11. PubMed ID: 27070416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Urokinase Receptor Levels Are Correlated with Focal Segmental Glomerulosclerosis Lesions in IgA Nephropathy: A Cohort Study from China.
    Guo SM; Han M; Chen MX; Ning Y; Pei GC; Li YQ; Dai W; Ge SW; Deng YJ; Guo YY; Li XQ; Haller H; Xu G; Rong S
    PLoS One; 2015; 10(9):e0138718. PubMed ID: 26380984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation.
    Harel E; Shoji J; Abraham V; Miller L; Laszik Z; Thurison T; King A; Olshen A; Leung J; Szabo G; Hann B; Høyer-Hansen G; Craik CS; Vincenti F
    Clin Transplant; 2019 Mar; 33(3):e13487. PubMed ID: 30689221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.
    Meijers B; Maas RJ; Sprangers B; Claes K; Poesen R; Bammens B; Naesens M; Deegens JK; Dietrich R; Storr M; Wetzels JF; Evenepoel P; Kuypers D
    Kidney Int; 2014 Mar; 85(3):636-40. PubMed ID: 24402090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis.
    Harita Y; Ishizuka K; Tanego A; Sugawara N; Chikamoto H; Akioka Y; Tsurumi H; Miura K; Gotoh Y; Tsujita M; Yamamoto T; Horike K; Takeda A; Oka A; Igarashi T; Hattori M
    Pediatr Nephrol; 2014 Sep; 29(9):1553-60. PubMed ID: 24705794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis.
    Lee JM; Yang JW; Kronbichler A; Eisenhut M; Kim G; Lee KH; Shin JI
    J Immunol Res; 2019; 2019():5679518. PubMed ID: 31089477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
    Alachkar N; Wei C; Arend LJ; Jackson AM; Racusen LC; Fornoni A; Burke G; Rabb H; Kakkad K; Reiser J; Estrella MM
    Transplantation; 2013 Oct; 96(7):649-56. PubMed ID: 23842190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates.
    Franco Palacios CR; Lieske JC; Wadei HM; Rule AD; Fervenza FC; Voskoboev N; Garovic VD; Zand L; Stegall MD; Cosio FG; Amer H
    Transplantation; 2013 Aug; 96(4):394-9. PubMed ID: 23736353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.